الفهرس 
Role of radiotherapy following surgical resection with curative intent for patients with stage IB-III gastric cancer - The NCI Cairo experience :A retrospective study 2009-2015
ContentsOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
Background The mainstay of treatment for potentially curable gastric carcinoma is radical gastrectomy. However, surgery alone is not a sufficient treatment for most gastric cancer patients, leading to poor long term survival and high incidence of locoregional recurrences. Several multimodality therapies have shown improvement in outcome compared to surgery alone. This restrospective study investigates the impact of adding adjuvant radiotherapy on locoregional control, overall survival and disease free survival in comparison to other treatment modalities not including radiotherapy. Methods Data of 79 patients with stage IB-III gastric cancer who underwent radical gastrectomy with curative intent at NCI during the period (2009-2015) were collected, analysed and followed up until 8/2017. The patients were split into two groups; group A including patients who received adjuvant chemoradiotherapy, and group B which includes patients who did not receive radiotherapy in their course of treatment. The locoregional control (LRC), overall survival (OS) and disease free survival (DFS) were compared for both groups, as was treatment related toxicity. Results Adjuvant chemoradiotherapy significantly improved locoregional control, overall survival and disease free survival. Patients in group A had a median LRC of 30 months in comparison to 20 months in group B (p=0.021). Median OS was 39 months and 29 months for group A and group B respectively (p=0.02). DFS was also significantly better in group A than group B (p=0.001). Treatment related toxicity, however, was higher in group A. Conclusion Patients with stage IB-III potentially curable gastric cancer benefit significantly from adding adjuvant radiotherapy following radical gastrectomy; in terms of improved survival and reduction of risk of locoregional recurrence